<DOC>
	<DOC>NCT00881452</DOC>
	<brief_summary>The purpose of this study is to determine whether CM-AT is safe and effective in treating the core symptoms of autism.</brief_summary>
	<brief_title>A Trial of CM-AT in Children With Autism</brief_title>
	<detailed_description>Autism is currently a significant cause of disability in the pediatric population. Treatment is based upon the observation that many children with autism do not digest protein. CM-AT is a proprietary enzyme that is designed as a powder taken three times a day.</detailed_description>
	<mesh_term>Autistic Disorder</mesh_term>
	<criteria>Meets the current Diagnostic and Statistical Manual for Mental Disorders (DSMIVTR) diagnostic criteria for autistic disorder (AD) Patient weighing &lt; 11kg (24.2 lbs.) Demonstrated previous allergy to porcine (pork) products Previous history of severe head trauma or stroke, seizure within one year of entering study or uncontrolled systemic disease Diagnosis of: HIV, cerebral palsy, endocrine disorder, pancreatic disease Within 30 days of starting the study, certain supplementation, chelation or dietary restriction (a 30 day washout period would be required for inclusion) Use of of any stimulant medication must be discontinued 5 days prior to entering the study. Subject must have a stable dose of SSRI's for at least 30 days.</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Autism</keyword>
</DOC>